Background and Objectives: In spite of increasing awareness, controversies prevail among Obstetrics and Gynaecology healthcare practitioners (HCPs) regarding use of hormone therapy in the management of menopause. This study aimed to assess the current understanding and practices among HCPs in menopause hormonal therapy (MHT) in Tier I and II cities in North and West India. Methods: An MHT certification training course was conducted for HCPs by Pfizer Ltd. in partnership with Indian Menopause Society (IMS), and a subsequent clinic-based cross-sectional interviewer-administered survey was carried out. A section of questions was devoted to obtain feedback on the course. A total of 140 HCPs volunteered to complete the survey and data was reported using descriptive statistics. Results: Eighty nine out of 140 (64%) HCPs believed that hormone therapy should be routinely prescribed to symptomatic menopausal women. The two most common factors influencing initiation of MHT were severity of symptoms (76%) and age at presentation (53%). Conjugated estrogens were the first choice for 44% of HCPs in their prescribing practice and 43% preferred prescribing MHT for 6–12 months. All HCPs reported that the course helped them improve their understanding about menopause and most important learning point was that hormone therapy should be started early. Additionally, 96% of HCPs felt that refresher training in MHT would be beneficial for their practice. Conclusions: Menopause hormonal therapy is gaining acceptance as a preferred treatment in menopause management. However, reservations exist regarding the duration of therapy. Regular training may reinforce confidence of HCPs in prescribing MHT.